Compare Bristol-Myers Squibb Co (BMY) vs FuelCell Energy Inc (FCEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs FuelCell Energy Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.61 (market cap $116.30B), while FuelCell Energy Inc trades at $20.29 (market cap $1.71B). The key difference: Bristol-Myers Squibb Co is far larger — about 68× FuelCell Energy Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while FuelCell Energy Inc pays none. Which is the better fit depends on your goals.
| BMY | FCEL | |
|---|---|---|
Market Cap | $116.30B | $1.71B |
Sector | Health | Industrials |
52-Week High | $62.37 | $36.01 |
52-Week Low | $42.60 | $3.92 |
Enterprise Value | $152.24B | $1.56B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
FuelCell Energy (FCEL) trades at $19.08, down 9.27% in the last session, as the stock consolidates following recent volatility. The company reported mixed Q1 2026 results with an earnings miss but continues to show revenue growth, with 2025 revenue reaching $158.16M. Technical indicators show a bearish trend with key support at $17-18 levels. Recent developments include a strategic partnership with Siemens to scale clean power solutions and a $225 million stock offering that caused temporary dilution concerns.
FCEL presents a high-risk opportunity with strong growth potential in the fuel cell sector but faces significant fundamental challenges. The company maintains negative profitability metrics and cash burn, though recent partnerships and data center demand provide catalysts. Analyst consensus is mixed with a $20.75 price target representing 8.8% upside, but investors should weigh the growth narrative against persistent losses and dilution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →
